Long-Term Survival And Gradual Recovery Of B Cells In Patients With Refractory Large B-Cell Lymphoma Treated With Axicabtagene Ciloleucel

A SUMMARY Long-Term Outcomes Following Donor-Derived Anti-CD19 CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia Patients Relapsed After Allogenic Stem Cell TransplantationZhang and colleagues presented key findings from 10 adult patients with B-cell acute lymphoblastic leukemia who received donor-derived anti-CD19 CAR T-cell therapy following relapse after allogeneic stem cell transplant (Abstract 500). Donor T cells were obtained from peripheral blood and infected with lentivirus carrying CD19 CAR plasmid. Recipients were pretreated with fludarabine, cyclophosphamide, and cytarabine before CAR T-cell infusion (median, 1.82 x 106 cells/kg). Peak expansion of CAR T cells was achieved after 7 to 14 days and decreased to a low level within 1 month of infusion. Peak serum levels of IL-6 and IL-2R were observed 5 to 7 days after CAR T-cell infusion. All patients experienced CRS events, which were mostly grade 1 or 2. No patients developed acute or new-onset graft-vs-host disease. After a median follow-up of 20.6 months, the 30-month OS was 51% and leukemia-free survival was 48%. Six patients were alive, and 1 patient required a second stem cell transplant.